Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 3/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104209 | 1.00 | CA1 (0.43) | CA1CA9CYP1A2IKBKBPRKCA | |
| SCHEMBL15334751 | 1.00 | CA1 (0.43) | CA1CA9CYP1A2IKBKBPRKCA | |
| SCHEMBL16804836 | 0.89 | CA1 (0.36) | CA1CA9 | |
| SCHEMBL16804841 | 0.89 | CA1 (0.36) | CA1CA9 | |
| SCHEMBL22268208 | 0.83 | CA1 (0.39) | CA1CA9 | |
| SCHEMBL19818951 | 0.83 | CA1 (0.39) | CA1CA9 | |
| SCHEMBL17323381 | 0.83 | CA1 (0.39) | CA1CA9 | |
| SCHEMBL12108375 | 0.79 | CYP2C9 (0.41) | CA1CA9CYP1A2PRKCA | |
| SCHEMBL12108376 | 0.79 | CYP2C9 (0.41) | CA1CA9CYP1A2PRKCA | |
| SCHEMBL12104238 | 0.79 | TSHR (0.41) | CA1CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | CA1 2892/4885CA9 419/4885CYP1A2 2920/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | CA1 3604/4885CA9 2039/4885CYP1A2 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.